ASSET PURCHASE AGREEMENT

                            ASSET PURCHASE AGREEMENT



                                 BY AND BETWEEN



                                 U.C. LASER LTD.



                                       AND


                      CRYSTALIX GROUP INTERNATIONAL, INC.,




                                   DATED AS OF



                                DECEMBER 29, 2005


















45931.0009\YOKENS\LAS\100852.3
<PAGE>
                            ASSET PURCHASE AGREEMENT

                  This ASSET PURCHASE  AGREEMENT is executed  December 29, 2005,
and  effective  as  of  January  1,  2006,  by  and  between   Crystalix   Group
International,  Inc.,  a  corporation  organized  under the laws of the State of
Nevada,  United States of America  ("CRYSTALIX")  and U.C. Laser Ltd., a company
organized  under the laws of the State of  Israel  of P.O.B 351  Karmiel  21613,
Israel (the "COMPANY").

                                    RECITALS

     A.    The  Company  wishes to sell to Crystalix,  and  Crystalix  wishes to
purchase  from the Company  (the  "TRANSACTION"),  all the assets of the Company
that are used in connection with the  manufacturing,  distribution and marketing
of the  Company's  decorative  images and products  (the  "COMPANY'S  BUSINESS")
including the Company's  Accounts  Receivable  (as defined  below),  the Company
Contracts (as defined below) and the Company's  worldwide,  exclusive license to
use the colored glass  technology  owned by Laser Glass Ltd. (the "COLORED GLASS
TECHNOLOGY  LICENSE") and the Company's shares in U.C. Laser, Inc. and CIC Laser
Technologies  Ltd.  (the  "PURCHASED   SUBSIDIARIES"  and,   collectively,   the
"PURCHASED ASSETS") and EXCLUDING the securities of UCLT Ltd. and of Laser Glass
Ltd. (the "EXCLUDED SUBSIDIARIES").

     B.    In  consideration of the transfer of the Purchased Assets,  Crystalix
will (i) assume the Assumed  Liabilities (as defined below),  and (ii) issue and
deliver to the Company  such number of shares of the Class B Preferred  Stock of
Crystalix (the "ISSUED Stock") as will  collectively have voting rights equal to
45% of all voting rights of Crystalix  Common Stock and any other class of Stock
as will be  outstanding  immediately  after the Closing,  determined  on a Fully
Diluted Basis (as defined  below).  The Issued Stock will be convertible  into a
total number of shares of Crystalix  Common  Stock as would,  immediately  after
such conversion,  represent 45% of all shares of capital Stock of Crystalix then
outstanding on a Fully Diluted Basis. The conversion  rights of the Issued Stock
will be exercisable  after the shareholders of Crystalix have approved a reverse
35 to 1 stock split which is  necessary  to permit  such  conversion  within the
number of shares of Common Stock  authorized in the Articles of Incorporation of
Crystalix, as referenced in Section 5.1 below.

     C.    The board of directors of each of Crystalix and the Company  believes
that it is in the best  interests of Crystalix  and the Company (as  applicable)
and  their  respective  shareholders  to  consummate  the  Transaction  and,  in
furtherance thereof, has approved the Transaction and this Agreement.

     D.    Each   of   the  Company  and  Crystalix  desires  to  make   certain
representations,  warranties,  covenants and  agreements in connection  with the
Transaction.

     NOW,   THEREFORE,   in    consideration   of   the   covenants,   premises,
representations  and warranties set forth herein,  intending to be legally bound
hereby, the parties agree as follows:



45931.0009\YOKENS\LAS\100852.3
<PAGE>


                                   ARTICLE 1
                                PURCHASE AND SALE

         1.1   PURCHASE  AND SALE  OF ASSETS; PURCHASE  AND ISSUANCE  OF SHARES;
ASSUMPTION OF LIABILITIES; GRANT OF LICENSE.

         Upon  the  terms  and  subject  to the  conditions  set  forth  in this
Agreement:

                (a)   The  Company  agrees  to sell,  convey,  transfer,  assign
and deliver to Crystalix and/or the Israeli  Subsidiary (as defined below),  and
Crystalix  agrees to  purchase  and  acquire  (directly  or through  the Israeli
Subsidiary)  from the Company,  at the Closing,  good title in and to all of the
Purchased  Assets,  including  but  not  limited  to (x) all of the  issued  and
outstanding share capital of the Purchased Subsidiaries,  and (y) the equipment,
Company  Contracts  (as  defined  below) and other  assets set forth in Schedule
1.1(a) hereto. The Purchased Assets shall be free and clear of all Liens, except
for (i) Liens  securing the Assumed  Liabilities  (as defined  below),  and (ii)
Liens for taxes not yet due and payable.

                (b) Crystalix agrees to issue and deliver to the Company, at the
Closing,  the  Issued  Stock,  free and  clear of all  liens,  pledge,  security
interests,   restrictions  on  transfer  (other  than  restrictions  imposed  by
applicable securities laws) or other encumbrances,  provided that twenty percent
(20%) of the shares of the Issued Stock (the "INDEMNITY  ESCROW  DEPOSIT") shall
be deposited  with an escrow agent  acceptable  to Crystalix  and the Company in
their  reasonable  discretion  (the  "ESCROW  AGENT")  pursuant to the terms and
conditions of an escrow agreement mutually acceptable to the Company,  Crystalix
and the Escrow Agent (the "ESCROW  AGREEMENT").  The  Indemnity  Escrow  Deposit
shall be held, invested and disbursed as provided in ARTICLE 7 of this Agreement
and the Escrow Agreement

                (c)  The  allocation  of  the  purchase  consideration among the
Purchased Assets is set forth in Schedule 1.1 (c).

                (d)  The  Company  agrees  to  assign  to  Crystalix  and/or the
Israeli  Subsidiary,  and  Crystalix  agrees to assume  and  become  responsible
(directly  or  through  the  Israeli  Subsidiary)  for,  all  of  the  Company's
Liabilities arising from or related to the Purchased Assets, which are listed on
Schedule  1.1(d) hereto (the "ASSUMED  LIABILITIES").  Crystalix and the Israeli
Subsidiary  will not assume or be responsible  for any other  Liabilities of the
Company.

                (e)  In  the event the Company is unable to transfer the Colored
Glass Technology  License,  it shall grant the Israeli Subsidiary a back-to-back
license, so that the Israeli Subsidiary will have the exclusive, worldwide right
to  exercise  all rights and  licenses  granted to the  Company  pursuant to the
Colored Glass Technology License, subject to applicable Law.

         1.2    CHANGE OF NAME.

         Following  the  Closing,  as further  provided  in  Section  5.1 below,
Crystalix  shall  undertake  all  corporate  actions,  and solicit all consents,
required to change its name to Seaena,  Inc.,  or, if such change of name is not
approved by any  competent  governmental  authority,  to any other similar name,
approved in advance by the Company.



                                      -2-
45931.0009\YOKENS\LAS\100852.3
<PAGE>


         1.3    ESTABLISHMENT OF AN ISRAELI SUBSIDIARY.

         Prior to the Closing,  Crystalix shall establish a wholly owned Israeli
registered subsidiary, which entity shall acquire and hold all rights, title and
interest  in the OCS  financed  Purchased  Assets  listed in  Schedule  1.3 (the
"Israeli  Subsidiary"),  including  the  Colored  Glass  Technology  License  or
back-to-back  license issued in lieu thereof as provided in Section 1.1(e).  The
name of the Israeli Subsidiary shall be Crystal Impressions (Israel) Ltd. or, if
such name is not approved by any  competent  governmental  authority,  any other
similar name, approved in advance by the Company. Any and all of the obligations
and  liabilities  assumed by Crystalix  under this Agreement with respect to the
purchase of the Purchased Assets set forth in Schedule 1.3 shall be assumed,  on
a joint and several basis, by the Israeli Subsidiary.

         1.4    BOARD OF DIRECTORS.

         Crystalix shall take all corporate  actions required to ensure that its
board of directors  immediately  following the Closing shall consist of five (5)
members, two (2) of which shall be Mr. Marshall D. Butler, and Dr. Zvi Dinstein.

         1.5    CLOSING.

         Unless this  Agreement is earlier  terminated  pursuant to Section 8.1,
the closing of the  Transaction  (the "Closing") is expected to take place on or
before January 31, 2006 and will take place as promptly as practicable, no later
than 5 Business Days  following  satisfaction  or waiver of the  conditions  set
forth in Article 6, at the offices of Naschitz,  Brandes & Co., 5 Tuval  Street,
Tel-Aviv, Israel, unless another place or time is agreed to by Crystalix and the
Company.

         1.6    ALL TRANSACTIONS  SIMULTANEOUS.  At  the Closing,  the following
actions  will  take  place,  each of which  shall  be  deemed  to have  occurred
simultaneously  (no  transaction  shall be deemed to have been  completed or any
document  delivered  until all such  transactions  have been  completed  and all
required documents delivered).

                (i)   The Company shall deliver to  Crystalix all  the documents
needed to consummate the transaction, including the following documents:

                      (a)   A  copy  of a resolution of the  Company's  board of
directors and the general meeting of the Company's  shareholders  approving this
Agreement and the Transaction;

                      (b)   All  documents  necessary  for the assignment of all
right,  title and interest in and to the patents and the  Intellectual  Property
included in the Purchased  Assets,  as set forth in schedule  1.6(i)(b)  hereto,
duly executed by the Company in a form acceptable to Crystalix;

                      (c)   Bills  of  sale   and   such  other  instruments  of
assignment,  transfer,  conveyance  and  endorsement  in the  form  attached  as
Schedule  1.6(i)(c) hereto,  required to transfer assign,  convey and deliver to
Crystalix or the Israeli Subsidiary the Purchased Assets as contemplated hereby;



                                      -3-
45931.0009\YOKENS\LAS\100852.3
<PAGE>


                      (d)  All share certificates representing shares of capital
stock of the Purchased  Subsidiaries,  duly  endorsed or with other  appropriate
instruments  of transfer  to  Crystalix  and all  necessary  authorizations  and
consents with respect to such transfers;

                      (e)  The Colored Glass Technology License executed by  the
licensor or back-to-back license as provided in Section 1.1(e);

                      (f)  Loan assumption documents for the Assumed Liabilities
("LOAN ASSUMPTION  DOCUMENTS")  acceptable to Crystalix  executed by the Company
and the respective lenders;

                      (g)  Shareholder  agreement (the "SHAREHOLDER  AGREEMENT")
executed by Crystalix, the Company and Kevin T. Ryan ("RYAN");

                      (h)  The  approval of the Israeli Tax Authority  exempting
Crystalix from actual payment of the Value Added Tax ("VAT") due with respect to
this  Transaction  and a certificate  from the Israeli  Income Tax  Commissioner
evidencing  an exemption  from the  withholding  of Taxes (the  "CERTIFICATE  OF
EXEMPTION");

                      (i)  A Consent Judgment  executed by U.C.  Laser,  Inc. in
the form attached as Exhibit A to this Agreement (the "CONSENT JUDGMENT");

                      (j)  A Settlement  Agreement  and Release by and among the
plaintiffs  named in the Consent  Judgment (the  "PLAINTIFFS"),  the Company and
U.C.  Laser,  Inc.  in the form  attached  as Exhibit B to this  Agreement  (the
"RELEASE"), executed by the Company and U.C. Laser, Inc.;

                      (k)  Assignments of any leases of real property  leased by
the Company  with the  written  consent of the  landlord if required  under such
leases or under leases to the Purchased  Subsidiaries  upon a change of control,
and any approvals  required for the assignment of each of the Company  Contracts
by the Company to Crystalix and/or the Israeli Subsidiary at the Closing;

                      (l)  Any approvals required under Section 6.1(i) below;

                      (m)  The executed Escrow Agreement;

                      (n)  A  Registration  Rights  Agreement  pursuant to which
the Company  shall be  entitled to  customary  registration  rights  which shall
include  unlimited  piggy-back  and S-3  registrations,  and a right to effect a
demand registration as of the termination of one year following the Closing, all
in accordance  with customary  terms and conditions  (the  "REGISTRATION  RIGHTS
AGREEMENT");

                      (o)  Opinion  letter  of the Company's counsel  concerning
(1)  authorization  of  the  Company  to  execute,  deliver,  and  perform  this
Agreement;  (2) authorization of the Company to transfer or grant a back-to-back
license to the Colored Glass Technology License; (3) such matters concerning the
share capital of the Purchased  Subsidiaries  as may be




                                      -4-
45931.0009\YOKENS\LAS\100852.3
<PAGE>


mutually agreed upon by Crystalix and the Company; and (4) such other matters as
may be mutually agreed upon by Crystalix and the Company;

                      (p)   Audited  financial statements of the Company for the
three (3) full years for which statements are available; and

                      (q)  A Certificate of the Company that all representations
and  warranties are true and correct as of the Closing and such other matters as
mutually agreed upon by the Parties.

               (ii)   Crystalix  shall  deliver to  the Company the Issued Stock
(less the shares of Issued Stock  constituting  the  Indemnity  Escrow  Deposit,
which shall be deposited  with the Escrow  Agent) and deliver to the Company the
following documents:

                      (a)   A  copy  of a  resolution  of  Crystalix's  board of
directors  approving  the issuance of the Issued  Stock to the Company,  and the
delivery of the Indemnity Escrow Deposit to the Escrow Agent;

                      (b)  A copy of the amended stock ledger listing the Issued
Stock;

                      (c)  Duly executed  stock  certificates  representing  the
Issued Stock (less the shares of Issued Stock  constituting the Indemnity Escrow
Deposit which shall be deposited with the Escrow Agent);

                      (d)  The  Colored Glass Technology License or back-to-back
license as provided in Section 1.1(e) executed by the Israeli  Subsidiary as the
licensee;

                      (e)  The Loan Assumption  Documents  acceptable to Company
executed by Crystalix and/or the Israeli Subsidiary;

                      (f)  The Shareholder Agreement executed by Ryan;

                      (g)  The  Consent  Judgment  executed   by   Laser  Design
International, Inc., and Norwood Operating Company;

                      (h)  The Release executed by the Plaintiffs;

                      (i)  The executed Escrow Agreement;

                      (j)  The executed Registration Rights Agreement; and

                      (k)  Opinion  letter  of  Crystalix's  counsel  concerning
(1) authorization of Crystalix to execute,  deliver, and perform this Agreement;
(2) such matters  concerning  the share  capital of Crystalix as may be mutually
agreed upon by Crystalix  and the Company;  and (3) such other matters as may be
mutually agreed upon by Crystalix and the Company; and




                                      -5-
45931.0009\YOKENS\LAS\100852.3
<PAGE>


                      (l)   A Certificate of Crystalix that all  representations
and  warranties are true and correct as of the Closing and such other matters as
mutually agreed upon by the Parties.

               (iii)  Crystalix shall deliver the Indemnity  Escrow  Deposit and
duly executed stock  certificates  representing  the Indemnity Escrow Deposit to
the Escrow Agent to be held pursuant to the Escrow Agreement.

         1.7   POSSESSION.

         Possession  of the  Purchased  Assets will be  delivered  to  Crystalix
immediately upon Closing.

                                   ARTICLE 2
                   REPRESENTATIONS AND WARRANTIES OF CRYSTALIX

         Crystalix hereby represents and warrants to the Company, as of the date
hereof and as of the Closing,  subject to the exceptions  specifically disclosed
in the attached disclosure schedule (the "CRYSTALIX  DISCLOSURE  SCHEDULE"),  as
follows:

         2.1   ORGANIZATION AND QUALIFICATION.

         Crystalix is a company duly  organized and in good  standing  under the
laws of the State of  Nevada,  and has full  corporate  power and  authority  to
conduct its business as now conducted and as currently  proposed to be conducted
and to own, use, license and lease its Intellectual Property.  Crystalix is duly
qualified,  licensed or admitted to do business and is in good  standing in each
jurisdiction in which such qualification is necessary.

         2.2   AUTHORITY RELATIVE TO THIS AGREEMENT.

         Crystalix has full corporate power and authority to execute and deliver
this  Agreement,  to perform its  obligations  hereunder and to  consummate  the
Transaction  contemplated  hereby.  Crystalix's  board of directors has approved
this  Agreement  and declared its  advisability.  The  execution and delivery by
Crystalix of this Agreement and the consummation by Crystalix of the Transaction
contemplated  hereby,  and  the  performance  by  Crystalix  of its  obligations
hereunder,  have been duly and validly authorized by all necessary action by the
board of directors of Crystalix, and no other action on the part of Crystalix is
required to authorize the execution,  delivery and performance of this Agreement
and the consummation by Crystalix of the Transaction  contemplated  hereby. This
Agreement  has been duly and validly  executed and  delivered by Crystalix  and,
assuming the due  authorization,  execution and delivery  hereof by the Company,
constitutes  a legal,  valid and binding  obligation  of  Crystalix  enforceable
against it in accordance with its terms,  except as the  enforceability  thereof
may be limited by bankruptcy, insolvency, fraudulent conveyance, reorganization,
moratorium  or other  similar Laws  relating to the  enforcement  of  creditors'
rights generally and by general  principles of equity.  This Transaction and the
issuance of the Issued Stock is not subject to any  preemptive  or other similar
rights.




                                      -6-
45931.0009\YOKENS\LAS\100852.3
<PAGE>

         2.3    CAPITAL STRUCTURE.

         The authorized share capital of Crystalix consists of:

                      (a)   300,000,000 shares of common stock, $.001  par value
each (the  "COMMON  STOCK"),  of which  278,274,972  shares of Common  Stock are
issued and outstanding as of the date hereof;

                      (b)   10,000,000 shares of Class A preferred stock,  $.001
par value each (the "PREFERRED A STOCK"),  of which no shares of Preferred Stock
are issued and outstanding as of the date hereof; and

                      (c)   5,000,000 shares of  preferred Class B stock,  $.001
par value each (the  "PREFERRED  B STOCK"),  of which no shares of  Preferred  B
Stock are issued and  outstanding  as of the date hereof (the  Preferred A Stock
together  with the  Preferred B Stock  shall be  referred  to as the  "PREFERRED
STOCK");

All of the issued and  outstanding  Common Stock and Preferred  Stock is validly
issued,  fully paid and non-assessable,  and have been issued in compliance with
all applicable Laws. There are no other classes of stock,  outstanding warrants,
options or loans in Crystalix and there are no preemptive  rights or agreements,
arrangements or  understandings to issue preemptive or other similar rights with
respect to the Transaction or the issuance or sale of the Issued Stock.

         2.4    NO CONFLICTS.

         The execution and delivery by Crystalix of this Agreement does not, and
the  performance  by Crystalix of its  obligations  under this Agreement and the
consummation  of the  Transaction  contemplated  hereby  does  not and  will not
conflict with or result in a violation or breach of any of the terms, conditions
or provisions of the Bylaws or Certificate of  Incorporation  of Crystalix,  any
agreement, contract, law, ordinance, regulation or other undertaking, obligation
or liability applicable to Crystalix.

         2.5    FINANCIAL STATEMENTS.

         Attached hereto as Schedule 2.5(a) of the Crystalix Disclosure Schedule
are the audited  financial  statements of Crystalix for the year ended  December
31, 2004 (including its balance sheet,  and its statements of income,  cash flow
and changes in  shareholders  equity,  and the notes  thereto) and the unaudited
financial statements for the nine months ended September 30, 2005 (together, the
"Crystalix  Financials").   The  Crystalix  Financials  have  been  prepared  in
accordance  with US GAAP applied on a consistent  basis  throughout  the periods
indicated therein and fairly and accurately present the financial  condition and
operating  results of Crystalix as of the dates and during the periods indicated
therein, subject, in the case of the September 30, 2005 Crystalix Financials, to
normal year-end adjustments, which adjustments will not be material in amount or
significance.  Except as set forth in Section 2.5(b) of the Crystalix Disclosure
Schedule,  since September 30, 2005,  there has been no change in any accounting
policies, principles, methods or practices, including any change with respect to
reserves  (whether  for bad debts,  contingent  liabilities  or  otherwise),  of
Crystalix.




                                      -7-
45931.0009\YOKENS\LAS\100852.3
<PAGE>


         2.6    ABSENCE OF CHANGES.

         Since  September  30,  2005 there has not been,  except as set forth in
Section 2.6 of the Crystalix  Disclosure  Schedule,  any material adverse effect
upon the business or condition  of Crystalix or any  occurrence  or event which,
individually  or in the  aggregate  could  be  reasonably  expected  to have any
material  adverse effect upon the business or condition of Crystalix.  Since the
beginning  of its 2005 fiscal year,  Crystalix  has operated its business in the
ordinary course of business and in accordance with past practice.

         2.7    NO UNDISCLOSED LIABILITIES.

         There are no Liabilities of, relating to or affecting  Crystalix or any
of its Assets and Properties,  other than  Liabilities  incurred in the ordinary
course of business  consistent  with past  practice and in  accordance  with the
provisions of this Agreement which,  individually and in the aggregate,  are not
material to the Business or Condition of Crystalix,  and are not for tort or for
breach of contract.

         2.8    LEGAL PROCEEDINGS.

         Except  as  set  forth  in  Section  2.8 of  the  Crystalix  Disclosure
Schedule:  (i) there are no Actions or Proceedings  pending or, to the knowledge
of  Crystalix,  threatened  against,  relating to or affecting  Crystalix or its
business; (ii) there are no facts or circumstances known to Crystalix that could
reasonably  be  expected  to give  rise to any  action  or  proceeding  against,
relating to or affecting  Crystalix or any of its business;  (iii) Crystalix has
not  received  notice,  and does not  otherwise  have  knowledge  of any  Orders
outstanding  against  Crystalix;  and (iv) Crystalix has not received notice and
does not  otherwise  have  knowledge  of any defects,  dangerous or  substandard
conditions in the products or materials sold, distributed, or currently proposed
to be sold or distributed  by Crystalix that could cause damage to property,  or
result in loss of use of property, or any claim, suit, demand for arbitration or
notice seeking damages for bodily injury, sickness, disease, death, or damage to
property, or loss of use of property.

         2.9    INTELLECTUAL PROPERTY.

         Except  as  set  forth  in  Section  2.9 of  the  Crystalix  Disclosure
Schedule,  Crystalix has all requisite right, title and interest in or valid and
enforceable  rights  under  Contracts  or Licenses  to use all the  Intellectual
Property necessary to the conduct of its business as presently conducted. All of
Crystalix's  Intellectual  Property is owned exclusively by Crystalix (excluding
Intellectual  Property  licensed to Crystalix under any License) and is free and
clear of any Liens. Crystalix (i) owns exclusively all trademarks, service marks
and trade names used by Crystalix in connection with the operation or conduct of
the business of  Crystalix;  and (ii) owns  exclusively,  and has good title to,
each copyrighted work and each other work of authorship that Crystalix otherwise
purports to own.

         2.10   DISCLOSURE.

         No  representation  or warranty  made by  Crystalix  contained  in this
Agreement, and no statement contained in the Crystalix Disclosure Schedule or in
any certificate,  list or other writing furnished to the Company pursuant to any
provision of this Agreement  (including the



                                      -8-
45931.0009\YOKENS\LAS\100852.3
<PAGE>


Crystalix  Financials) contains any untrue statement of a material fact or omits
to state a material  fact  necessary in order to make the  statements  herein or
therein,  in the light of the  circumstances  under  which they were  made,  not
misleading.  Crystalix  has provided the Company with all of the  Contracts  and
Licenses heretofore requested on behalf of the Company in writing, and all other
material information concerning Crystalix in the possession,  custody or control
of Crystalix.

         2.11   EXPERIENCE; RECEIPT OF INFORMATION.

         Crystalix has such  knowledge and  experience in financial and business
matters as to be  capable of  evaluating  the merits and risks  relating  to the
Transaction,  and has reviewed  and  inspected  all of the data and  information
provided to it by the Company in connection with this  Agreement.  Crystalix has
been furnished by the Company with the documents and  information  regarding the
Company  in  response  to  Crystalix's   request,  and  has  been  afforded  the
opportunity  to ask  questions  of and  receive  answers  from  duly  authorized
officers  or other  representatives  of the  Company  concerning  the  Company's
business, assets and financial position.

                                   ARTICLE 3
                  REPRESENTATIONS AND WARRANTIES OF THE COMPANY

         The Company hereby represents and warrants to Crystalix, as of the date
hereof and as of the Closing,  subject to the exceptions  specifically disclosed
in the attached  disclosure  schedule (the "COMPANY  DISCLOSURE  SCHEDULE"),  as
follows:

         3.1    ORGANIZATION AND QUALIFICATION.

         The Company is a private  company duly  organized and validly  existing
under the Laws of the State of Israel.  U.C.  Laser,  Inc. is a private  company
duly and validly  existing  under the Laws of the State of  Delaware.  CIC Laser
Technologies Ltd. is a private company duly organized and validly existing under
the laws of the  People's  Republic  of  China.  All such  companies  have  full
corporate  power and authority to conduct their business as now conducted and as
currently  proposed to be conducted.  The Company has full  corporate  power and
authority to own, use, license and lease the Purchased  Assets.  The Company and
the  Purchased  Subsidiaries  are fully  qualified,  licensed  or admitted to do
business,  and  are in  good  standing,  in  each  jurisdiction  in  which  such
qualification  is  necessary.  Other  than the  Purchased  Subsidiaries  and the
Excluded  Subsidiaries,  the  Company  does not have  any  subsidiaries  or own,
beneficially or otherwise,  any shares or other  securities of, or any direct or
indirect  interest of any nature in, any other  entity.  The Company and each of
the Purchased  Subsidiaries  have not conducted any business  under or otherwise
used, for any purpose or in any jurisdiction, any fictitious name, assumed name,
trade name or other name.

         3.2    AUTHORITY RELATIVE TO THIS AGREEMENT.

         The  Company  has full  corporate  power and  authority  to execute and
deliver this Agreement,  to perform its obligations  hereunder and to consummate
the  Transaction  contemplated  hereby.  The  Company's  board of directors  has
approved  this  Agreement  and  declared its  advisability.  The  execution  and
delivery by the Company of this Agreement and the consummation by the Company of
the Transaction  contemplated  hereby, and the performance by the Company of its
obligations  hereunder,  have been duly and validly  authorized by all necessary


                                      -9-
45931.0009\YOKENS\LAS\100852.3
<PAGE>


action by the Company  (save for approval by a general  meeting of the Company),
and no other  action on the part of the Company  (save for approval by a general
meeting of the Company) is required to  authorize  the  execution,  delivery and
performance  of  this  Agreement  and the  consummation  by the  Company  of the
Transaction  contemplated  hereby.  This  Agreement  has been  duly and  validly
executed  and  delivered by the Company  and,  assuming  the due  authorization,
execution  and delivery  hereof by  Crystalix,  constitutes  a legal,  valid and
binding obligation of the Company  enforceable against it in accordance with its
terms,  except as the  enforceability  thereof  may be  limited  by  bankruptcy,
insolvency, fraudulent conveyance,  reorganization,  moratorium or other similar
Laws relating to the enforcement of creditors'  rights  generally and by general
principles  of  equity.  The  Transaction  and the  transfer  of  shares  in the
Purchased  Subsidiaries  are not subject to any right of first  refusal or other
similar rights.

         3.3    NO CONFLICTS.

         The execution and delivery by the Company of this  Agreement  does not,
and the performance by the Company of its  obligations  under this Agreement and
the  consummation of the Transaction  contemplated  hereby does not and will not
conflict with or result in a violation or breach of any of the terms, conditions
or  provisions  of the Articles of  Association  of the Company or the Purchased
Subsidiaries,  any  agreement,  Contract,  Law,  ordinance,  regulation or other
undertaking,  obligation or Liability applicable to the Company or the Purchased
Subsidiaries.

         3.4    FINANCIAL STATEMENTS.

         Attached hereto as Schedule 3.4(a) of the Company  Disclosure  Schedule
are the  audited  financial  statements  of the Company  (including  its balance
sheet,  and its  statements  of income,  cash flow and  changes in  shareholders
equity,  and the notes  thereto) and the Purchased  Subsidiaries  for the period
ending December 31, 2004 and the unaudited  financial  statements of the Company
and the  Purchased  Subsidiaries  for  the  period  ending  September  30,  2005
(collectively, the "Company's Financials"). The Company's Financials are correct
and complete in all material  respects and have been prepared in accordance with
Israeli or US GAAP (as applicable)  applied on a consistent basis throughout the
periods  indicated  therein  and fairly and  accurately  present  the  financial
condition and operating  results of the Company and the Purchased  Subsidiaries,
as  applicable,  as of the dates  and  during  the  periods  indicated  therein,
subject, in the case of the September 30, 2005 Company's  Financials,  to normal
year-end  adjustments,  which  adjustments  will not be  material  in  amount or
significance  and  except  that  the  Company's   Financials  does  not  contain
footnotes.  Except as set forth in  Section  3.4(b)  of the  Company  Disclosure
Schedule,  since September 30, 2005,  there has been no change in any accounting
policies, principles, methods or practices, including any change with respect to
reserves (whether for bad debts,  contingent  Liabilities or otherwise),  of the
Company or the Purchased Subsidiaries, as applicable.

         3.5    ABSENCE OF CHANGES.

         Since  September  30,  2005,  except as set forth in Section 3.5 of the
Company Disclosure Schedule, there has not been any material adverse effect upon
the  Business or  Condition  of the Company or any  occurrence  or event  which,
individually  or in the  aggregate  could  be  reasonably



                                      -10-
45931.0009\YOKENS\LAS\100852.3
<PAGE>


expected to have any material  adverse  effect upon the Business or Condition of
the Company.  Since the  beginning of its 2005 fiscal year,  the Company and the
Purchased Subsidiaries have operated their respective businesses in the Ordinary
Course of Business and in accordance with past practice.

         3.6    LEGAL PROCEEDINGS.

         Except as set forth in Section 3.6 of the Company Disclosure  Schedule:
(i) there are no Actions or Proceedings pending or, to the knowledge the Company
or the Purchased Subsidiaries,  threatened against, relating to or affecting any
of the Purchased Assets or the Company; (ii) there are no facts or circumstances
known to the Company or the  Purchased  Subsidiaries  that could  reasonably  be
expected  to give  rise to any  action or  proceeding  against,  relating  to or
affecting  the  Purchased  Assets  or the  Company;  (iii)  the  Company  or the
Purchased  Subsidiaries  have not received  notice,  and do not  otherwise  have
knowledge of any Orders  outstanding  against any of the Purchased Assets or the
Company;  and (iv) the Company or the Purchased  Subsidiaries  have not received
notice  and  do not  otherwise  have  knowledge  of any  defects,  dangerous  or
substandard  conditions  in the  Purchased  Assets or in any of the  products or
materials sold,  distributed or currently  proposed to be sold or distributed by
the  Purchased  Subsidiaries  that could cause damage to property,  or result in
loss of use of property,  or any claim,  suit,  demand for arbitration or notice
seeking  damages  for bodily  injury,  sickness,  disease,  death,  or damage to
property, or loss of use of property.

         3.7    NO UNDISCLOSED LIABILITIES.

         Except as reflected  or reserved  against in the  Company's  Financials
(including  the notes  thereto)  or as  disclosed  in Section 3.7 of the Company
Disclosure  Schedule (which  includes a list of the Liabilities  which relate to
the Purchased Assets), there are no Liabilities of, relating to or affecting the
Purchased  Assets,  other than  Liabilities  incurred in the Ordinary  Course of
Business  consistent  with past practice or in accordance with the provisions of
this Agreement which, individually and in the aggregate, are not material to the
Business or  Condition  of the Company or to the  Business or  Condition  of the
Purchased Assets, and are not for tort or for breach of Contract.

         3.8    COLORED GLASS TECHNOLOGY LICENSE.

         The  Company  has made  available  to  Crystalix  a true,  correct  and
complete  copy of the  Colored  Glass  Technology  License  and  any  underlying
patents,  as  presently  in effect.  The  Company is not,  and to the  Company's
knowledge,  no party to the Colored Glass  Technology  License is, in default in
the discharge of any obligation  under, or in the performance of any covenant or
obligation  to be  performed  by such  party  pursuant  to,  the  Colored  Glass
Technology  License.  The Company has not received  any written  notice or claim
challenging  or  questioning  the validity or  enforceability  of the  Company's
rights under the Colored Glass  Technology  License and the Company is not aware
of any reasonable basis for such claim. Pursuant to the Colored Glass Technology
License,  the  Company,  and upon the transfer of such license or the grant of a
back-to-back



                                      -11-
45931.0009\YOKENS\LAS\100852.3
<PAGE>

license to the Israeli Subsidiary,  the Israeli Subsidiary will have a worldwide
exclusive  license to use the colored glass technology owned by Laser Glass Ltd.
In  addition,  the  Company's  rights,  and upon the transfer of such license or
grant  of  a  back-to-back  license  to  the  Israeli  Subsidiary,  the  Israeli
Subsidiary's  rights,  under the current license will expire or may otherwise be
terminated only in accordance with terms and conditions set forth in the Colored
Glass Technology License.

         3.9    CONTRACTS.

         The Company has made available to Crystalix true,  correct and complete
copies of all of the Contracts,  including  Licenses,  to which the Company is a
party  which  are  related  to the  Company's  Business  or to which  any of the
Purchased Subsidiaries is a party (the "Company Contracts"), all as presently in
effect. The Company and the Purchased Subsidiaries are not, and to the Company's
and the Purchased Subsidiaries'  knowledge, no third party to any of the Company
Contracts is, in default in the  discharge of any  obligation  under,  or in the
performance of any covenant or obligation to be performed by such party pursuant
to, any  Company  Contract.  The  Company is  entitled  to assign its rights and
obligations  under each  Company  Contract  to which it is a party to  Crystalix
and/or  the  Israeli  Subsidiary  or will be  entitled  to assign its rights and
obligations  under  each  Company  Contract  to  Crystalix  and/or  the  Israeli
Subsidiary  with the  prior  approval  of one or more  parties  to such  Company
Contract.  Except for (a) the Company  Contracts  involving the payment by or to
the  Company  of Fifty  Thousand  Dollars  ($50,000)  or less  within any twelve
(12)-month period from the date of this Agreement,  and (b) as listed in Section
3.9 of the Company Disclosure Schedule, neither the Company, with respect to the
Company's Business, nor either of the Purchased  Subsidiaries,  is a party to or
bound by any:

                (i)   Contract, including any License, not made in the  Ordinary
Course of Business;

                (ii) Bonus, pension, profit sharing, retirement, stock purchase,
hospitalization,  medical  reimbursement,  insurance,  or other  plan  providing
employee benefits;

                (iii) Lease  with  respect  to  any property, real or  personal,
whether as lessor or lessee;

                (iv)  Continuing Contract for the future  purchase of materials,
supplies, or equipment;

                (v)   Contract or commitment for capital expenditures;

                (vi)  Contract, including  any License, with a remaining term of
more than one (1) year from the date of this  Agreement  that is not  terminable
upon thirty (30) days notice;

                (vii)  Contract  for the lease,  operation,  or  maintenance  of
any machinery or equipment  with a remaining term of more than one (1) year from
the date of this Agreement that is not terminable  upon thirty (30) days notice;
or

                (viii)   Contract, including any  License, to pay any  royalties
or fees with respect to any sales of the Company.




                                      -12-
45931.0009\YOKENS\LAS\100852.3
<PAGE>


         3.10   INTELLECTUAL PROPERTY.

         Except as set forth in Section 3.10 of the Company Disclosure Schedule,
the Company and each Purchased  Subsidiary have all requisite  right,  title and
interest in or valid and enforceable rights under Contracts, including Licenses,
to use  all  the  Intellectual  Property  necessary  to  the  conduct  of  their
respective business as presently  conducted.  All of the Company's  Intellectual
Property is owned exclusively by the Company  (excluding  Intellectual  Property
licensed to the Company  under any  License) and is free and clear of any Liens.
All the Intellectual  Property of each Purchased Subsidiary is owned exclusively
by the relevant Purchased Subsidiary  (excluding  Intellectual Property licensed
to each  Purchased  Subsidiary  under any  License) and is free and clear of any
Liens.  The Company  and each  Purchased  Subsidiary  (i) owns  exclusively  all
trademarks,  service marks and trade names  respectively used by the Company and
each  Purchased  Subsidiary in  connection  with the operation or conduct of the
Company's Business or of such Purchased  Subsidiary's  Business,  as applicable;
and (ii) owns exclusively, and has good title to, each copyrighted work and each
other  work of  authorship  that  the  Company  and  each  Purchased  Subsidiary
otherwise purports to own.

         All of